Detalhe da pesquisa
1.
Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
CA Cancer J Clin
; 69(4): 280-304, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31099893
2.
Disparities in clinical trial enrollment at a Canadian comprehensive cancer center: A 15-year retrospective study.
Cancer
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662430
3.
High grade adverse event reporting and enrolment in gynecologic oncology clinical trials.
Gynecol Oncol
; 185: 1-7, 2024 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342004
4.
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecol Oncol
; 185: 128-137, 2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38412736
5.
Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening.
Proc Natl Acad Sci U S A
; 118(25)2021 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161278
6.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer
; 128(2): 255-265, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482193
7.
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program.
Haematologica
; 108(1): 196-206, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35734926
8.
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Gynecol Oncol
; 172: 121-129, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37030280
9.
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
Gynecol Oncol
; 178: 110-118, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839313
10.
Emerging peptide therapeutics for the treatment of ovarian cancer.
Expert Opin Emerg Drugs
; 28(2): 129-144, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37282529
11.
Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study.
Support Care Cancer
; 31(7): 404, 2023 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37341839
12.
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Int J Gynecol Cancer
; 33(8): 1208-1214, 2023 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37380217
13.
Management of Malignant Bowel Obstruction: An Innovative Proactive Outpatient Nurse-Led Model of Care for Patients With Advanced Gynecologic Cancer.
J Nurs Care Qual
; 38(1): 69-75, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36214674
14.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(4): 465-478, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35298906
15.
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Lancet Oncol
; 23(8): e374-e384, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35901833
16.
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
; 397(10271): 281-292, 2021 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33485453
17.
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.
Gynecol Oncol
; 167(2): 226-233, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36055813
18.
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Gynecol Oncol
; 165(1): 40-48, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35115180
19.
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Gynecol Oncol
; 166(2): 254-262, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35718565
20.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273926